As EMM is often associated with drug resistance, we tested the levels of VCAM1, HGFA and PEDF in the plasma of patients whose CD138+ myeloma cells had been evaluated by ex vivo drug sensitivity resistance testing (DSRT) (n = 44) [22,23]. This evidence concerns the gene SDC1 and plasma cell myeloma.